ECTS2014 Poster Presentations Osteoporosis: treatment (68 abstracts)
Institute of revmatology, Na Slupi 4, Prague 2, Czech Republic.
Objectives: To confirm effect of intravenous treatment with ibandronate every three months in common population of postmenopausal women.
Methods: Patients with postmenopausal osteoporosis, who fulfil ACR criteria for postmenopausal osteoporosis and were treated with intravenous ibandronate for two years, underwent DEXA examination.
Results: A 50 women suffering from postmenopausal osteoporosis were treated with ibandronate i.v. every three during 2 years. (It means 8 doses of i.v. ibandronate.) They were examinated between May 2010 and April 2013. Average age was 71.2 years, range 4786 years.The previous antiosteoporotic treatment had 44/50=88%.
The previous osteoporotic fracture had 28/50=56%. Average time from menopause was 21.3−9.2 years, range 035 years. Average time of previous antiosteoporotic treatment was 3.3−0.5 years, range 016 years.
BMD (g/cm2)Trend New fractures 0
L spine +3.3% after 1 year,
+1.9% after 2 years
hip +0.5\.+0.9%,
neck +2.7\.+3.3%
Difference (T-score) after 1 year Difference (T-score) after 2 years compare to baseline
L-spine: P=0.23 L-spine: P=0.23
total hip: P=0.22 total hip: P=0.95
neck: P=0.001 neck: P < 0.0001
There was no difference in all regions between the first and secon years.
Difference (g/cm2) after 1 year Difference (g/cm2) after 2 years
L-spine: P=0.004 L-spine: P=0.009
hip: P=0.933 hip: P=0.96
neck: P=0.004 neck: P=0.18
There was no difference in all regions between the 1 and 2 years.
Conclusion: These results of common population of postmenopausal women confirm BMD gain in all regions especially after the 1 year of treatment, but significant gain in T-score and g/cm2 was only in femur neck and significant gain in g/cm2 was also in L spine. After the first year there was stagnation.
Postmenopausal osteoporosis, BMD, T-score, ibandronate